Definium's LSD therapy eased anxiety in second large trial

Definium Therapeutics reported that its LSD therapy (DT120) helped patients with anxiety in a second late-stage trial, with patients experiencing a 9.8-point drop on the Hamilton Anxiety Rating Scale versus a 4.7-point drop for placebo—a 5.1-point difference similar to the first trial and larger than many other anxiety therapies. The company is now positioned to seek the first FDA approval of a psychedelic drug for anxiety treatment.

This is trial data; approval is not yet assured. The article does not provide the full trial protocol or safety profile.